Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75427 | 0.99 | HRH3 (0.61) | HRH3HRH1HRH4KCNH2ADRA1A | |
| SCHEMBL74673 | 0.87 | HRH3 (0.59) | HRH3HRH1HRH4KCNH2ADRA1A | |
| SCHEMBL75477 | 0.86 | HRH3 (0.59) | HRH3HRH1HRH4KCNH2 | |
| SCHEMBL75466 | 0.85 | HRH3 (0.60) | HRH3HRH1HRH4KCNH2 | |
| SCHEMBL73547 | 0.84 | HRH3 (0.56) | HRH3HRH1HRH4KCNH2ADRA1A | |
| SCHEMBL74060 | 0.84 | HRH3 (0.52) | HRH3HRH1HRH4KCNH2ADRA1A | |
| SCHEMBL75129 | 0.84 | HRH3 (0.56) | HRH3HRH1HRH4KCNH2ADRA1A | |
| SCHEMBL4470017 | 0.83 | HRH3 (0.70) | HRH3KCNH2ADRA1A | |
| SCHEMBL75426 | 0.83 | LTA4H (0.48) | HRH3KCNH2 | |
| SCHEMBL74537 | 0.83 | CYP2D6 (0.50) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945206-B1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2013-04-24 | — | — | EP | claimed |
| US-8129424-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2012-03-06 | — | — | US | claimed |
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-03-10 | — | — | US | claimed |
| EP-1945206-B1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-1945206-B1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8129424-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129424-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129424-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-03-10 | — | — | US | disclosed |
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-03-10 | — | — | US | disclosed |
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-03-10 | — | — | US | disclosed |
| US-7528262-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528262-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090036446-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | BENNANI YOUSSEF L | 2009-02-05 | — | — | US | disclosed |
| US-20090036446-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | BENNANI YOUSSEF L | 2009-02-05 | — | — | US | disclosed |
| US-20090036446-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | BENNANI YOUSSEF L | 2009-02-05 | — | — | US | disclosed |
| US-20070161676-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161676-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161676-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007047775-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036446-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | HRH3, HCRTR1, HCRTR2 | HRH3 1/4885HRH1 9/4885HRH4 4/4885 |
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | HRH3, HCRTR1, HCRTR2 | HRH3 1/4885HRH1 9/4885HRH4 4/4885 |
| US-20070161676-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | HRH3, HCRTR1, HCRTR2 | HRH3 1/4885HRH1 9/4885HRH4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.